Australian study suggests children, infants only need one H1N1 vaccine dose.
A study by Australian researchers found children and infants only need one does of H1N1 vaccine for effective immunity to the disease. If confirmed, the results "could help damp the spread of the virus by reducing the logistical complications associated with the currently recommended regimen of two doses." However, US health authorities "will not change their recommendations for children." In an editorial accompanying the report in the Journal of the American Medical Association, they note "that the Australian study used twice the dosage of viral antigen found in US vaccines" and the study directly contradicts previous research.
Dr. Anthony Fiore, at the CDC's National Center for Infectious Diseases, wrote in the editorial, "Until you can show that a single dose is as effective as two, it's probably too soon to pull away from the two-dose recommendation."
Cephalon's Treanda may delay cancer growth better than CHOP cocktail. Cephalon, Inc.'s cancer drug Treanda [bendamustine] worked better than a standard chemotherapy regimen when paired with Roche Holding AG's Rituxan [rituximab] to slow the progression of certain lymphomas," according to findings reported at the American Society of Hematology meeting. The standard cocktail, known as CHOP, "includes four medicines: the chemotherapies cyclophosphamide, adriamycin, vincristine and the steroid prednisone." Researchers found that in patients with "cancers known as follicular, indolent, or mantle-cell lymphomas," Treanda "delayed cancer growth for 55 months, compared with 35 months for those taking the regimen known as CHOP."
Bendamustine (Treanda) could replace the so-called CHOP regimen as the optimal partner with rituximab (Rituxan) as the standard first-line treatment for indolent and mantle cell lymphomas, researchers said." In fact, "the combination of bendamustine and rituximab showed substantially lower toxicity and better complete response rates in a randomized Phase III trial," according to a German researcher. The researcher also said the bendamustine-rituximab combination "'has the potential to become the new standard of care' for follicular lymphoma, mantle cell lymphoma, and other indolent forms of lymphoma."
Defibrotide may prevent VOD in children, adolescents undergoing stem cell transplants.
The investigational drug defibrotide helped prevent hepatic veno-occlusive disease (VOD) in children and adolescents undergoing stem cell transplants for leukemia, researchers said" at the American Society of Hematology's meeting. Selim Corbacioglu, MD, of Germany's University of Ulm, said "VOD developed in 12% of young patients receiving the drug prophylactically, compared with 20% of a placebo group in a randomized, 360-patient trial." Corbacioglu also said that overall, "VOD at day 30 post-transplant was seen in 23% of infants, 14% of children, and 13% of adolescents," and "defibrotide was significantly more effective than placebo in several secondary endpoints."
Omapro confirms results in study of patients with CML.
ChemGenex Pharmaceuticals Ltd., an unprofitable Australian drugmaker, said its experimental leukemia drug," called Omapro (omacetaxine mepesuccinate), "cleared the disease in 86 percent of patients, confirming results under review by US and European regulators." The study of 81 patients with "chronic myeloid leukemia, or CML," showed that the drug "also eradicated the disease from bone marrow in 18 percent of patients with an early stage of the blood cancer, potentially allowing them to receive marrow transplants and be cured of the disease." The drug also "is the first to treat the five percent of CML patients who have a gene mutation that makes them resistant to Novartis AG's Gleevec" [imatinib], and ChemGenex "has said it expects FDA approval by mid-2010."
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn